A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ADMYRA
- Sponsors HEXAL; Sandoz
- 08 Dec 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 16 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2017.